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Aim To evaluate a standardised MRI acquisition protocol and a new image rating
scale for disease severity in patients with progressive supranuclear palsy (PSP) and
multiple systems atrophy (MSA) in a large multicentre study.Methods The MRI
protocol consisted of two-dimensional sagittal and axial T1, axial PD, and axial and
coronal T2 weighted acquisitions. The 32 item ordinal scale evaluated abnormalities
within the basal ganglia and posterior fossa, blind to diagnosis. Among 760 patients
in the study population (PSP=362, MSA=398), 627 had per protocol images
(PSP=297, MSA=330). Intra-rater (n=60) and inter-rater (n=555) reliability were
assessed through Cohen's statistic, and scale structure through principal component
analysis (PCA) (n=441). Internal consistency and reliability were checked.
Discriminant and predictive validity of extracted factors and total scores were tested
for disease severity as per clinical diagnosis. Results Intra-rater and inter-rater
reliability were acceptable for 25 (78%) of the items scored (≥0.41). PCA revealed
four meaningful clusters of covarying parameters (factor (F) F1: brainstem and
cerebellum; F2: midbrain; F3: putamen; F4: other basal ganglia) with good to
excellent internal consistency (Cronbach α 0.75–0.93) and moderate to excellent
reliability (intraclass coefficient: F1: 0.92; F2: 0.79; F3: 0.71; F4: 0.49). The total
score significantly discriminated for disease severity or diagnosis; factorial scores
differentially discriminated for disease severity according to diagnosis (PSP: F1–F2;
MSA: F2–F3). The total score was significantly related to survival in PSP (p<0.0007)
or MSA (p<0.0005), indicating good predictive validity. Conclusions The scale is
suitable for use in the context of multicentre studies and can reliably and consistently
measure MRI abnormalities in PSP and MSA. Clinical Trial Registration Number The
study protocol was filed in the open clinical trial registry
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